Esomeprazole Market
Global Esomeprazole Market Size, Share & Trends Analysis Report, By Disease (Erosive Esophagitis, Gastroesophageal Reflux Disease, Helicobacter Pylori Infection, Other), By Type (Branded and Generic), By Dosage Type (Capsules & Tablets, Injections, and Other) and Forecast, 2020-2026
The esomeprazole market is expected to show a modest growth rate during the forecast period 2020-2026. Esomeprazole is a proton pump inhibitor that is used to reduce the amount of acid in the stomach. Esomeprazole is sold by AstraZeneca plc under the brand name Nexium. It was first approved in February 2002 by the US FDA for the treatment of heartburn and other symptoms associated with gastroesophageal reflux disease (GERD) and also for erosive esophagitis.
Until 2019, AstraZeneca plc has earned more than $52.5 billion from the sales of Nexium all across the globe. In 2019, AstraZeneca plc generated revenue of around $1.5 billion by the sales of Nexium as compared to $1.7 billion and $1.9 billion in 2018 and 2017 respectively. The downfall in revenue is due to increasing generic versions (except Japan) of the drug and disinvestment of Nexium in Europe. As per AstraZeneca plc, Nexium revenue is significantly increasing in China and Japan. Moreover, in October 2018, the company sold its Nexium rights to Grünenthal GmbH in Europe. Grünenthal GmbH had made an upfront payment of $700 million along with milestone and sales-related payment of around $90 million.
High incidence of Gastroesophageal reflux disease (GERD) is one of the major factors for the growth of the market all across the globe. As per the US Medical Expenditure Panel Survey, Esomeprazole's prescription was around 9 million in 2017. However, these numbers are reducing continuously since the last decade. As in 2011, the esomeprazole prescription was around 25 million. The presence of alternative proton pump inhibitors is one of the restraining factors for the growth of the market. Omeprazole, a chemical isomer esomeprazole was the most prescribed proton pump inhibitor in 2017 in the US that is used to treat GERD. The prescription of omeprazole was around 58.8 million in 2017. The cost of omeprazole is also lower as compared to esomeprazole. However, in many studies, better results of esomeprazole are found over omeprazole which is a positive factor for the growth of the market.
Market Segmentation
The global esomeprazole market is segmented based on disease, type, and dosage type. On the basis of disease, the market is further segmented into erosive esophagitis, gastroesophageal reflux disease, helicobacter pylori infection, and others. During the forecast period, gastroesophageal reflux disease is expected to hold a major market share during the forecast period. By type, the market is bifurcated into branded and generic drugs. A downfall in the branded drug revenue is expected whereas a significant growth in generic drugs will be witnessed during the forecast period. A number of generic drug manufacturing companies have got drug approval for esomeprazole, which is augmenting the segment growth.
By dosage type, the market is segmented into capsules & tablets, injections, and others. Delayed-release capsules, suspension, packets, and injection are the prescription drug whereas capsules, mini capsules, and tablets are OTC drugs in the US. Generic prescription drugs are generally covered in insurance in the US.
Global Esomeprazole Market Share by Dosage Type, 2019 (%)
Regional Outlook
On the basis of geography, the global esomeprazole market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). During the forecast period, North America is expected to have a significant market share. The high cost of drugs and coverage of esomeprazole in insurance is one of the major factors for the significant market share of the region. In 2019, Nexium generated a revenue of $218 million from the US alone. Europe is also expected to hold a major market share with a modest growth rate.
Asia-Pacific is expected to have a major market share with a significant growth rate during the forecast period. High revenue of Nexium in Japan and China, US FDA approval for esomeprazole to various generic manufacturing companies in India, and China are some of the motivating factors for the market.
Global Esomeprazole Market Growth, by Region 2020-2026
Market Players Outlook
The esomeprazole market is consolidated in nature and a few major market players are operating in the market. Some of the major market players include AbbVie Inc, Sanofi SA, Mylan NV, Novartis AG, Teva Pharmaceutical Industries Ltd., Grünenthal GmbH, Glenmark Pharmaceuticals Inc., and Mylan N.V.The market players are adopting growth strategies including mergers & acquisitions, product approvals, and partnerships & collaborations to gain a competitive edge in the market. For instance, in May 2019, Glenmark Pharmaceuticals Inc. got the final US FDA approval for Esomeprazole Magnesium Delayed-Release Capsules USP, 20 mg, and 40 mg. The approval will aid the company to grow its business in the US.
The Report Covers
- Market value data analysis of 2019 and forecast to 2026.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global Esomeprazole market.
- Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdowns
1.2.1. By Segments
1.2.2. By Geography
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. AbbVie Inc
3.3.1.1. Overview
3.3.1.2. Financial Analysis
3.3.1.3. SWOT Analysis
3.3.1.4. Recent Developments
3.3.2. Sanofi SA
3.3.2.1. Overview
3.3.2.2. Financial Analysis
3.3.2.3. SWOT Analysis
3.3.2.4. Recent Developments
3.3.3. Mylan NV
3.3.3.1. Overview
3.3.3.2. Financial Analysis
3.3.3.3. SWOT Analysis
3.3.3.4. Recent Developments
3.3.4. Novartis AG
3.3.4.1. Overview
3.3.4.2. Financial Analysis
3.3.4.3. SWOT Analysis
3.3.4.4. Recent Developments
3.3.5. Teva Pharmaceutical Industries Ltd.
3.3.5.1. Overview
3.3.5.2. Financial Analysis
3.3.5.3. SWOT Analysis
3.3.5.4. Recent Developments
4. Market Determinants
4.1 Motivators
4.2 Restraints
4.3 Opportunities
5. Market Segmentation
5.1. Global Esomeprazole Market by Disease
5.1.1. Erosive Esophagitis
5.1.2. Gastroesophageal Reflux Disease
5.1.3. Helicobacter Pylori Infection
5.1.4. Other
5.2. Global Esomeprazole Market by Type
5.2.1. Branded
5.2.2. Generic
5.3. Global Esomeprazole Market by Dosage Type
5.3.1. Capsules & Tablets
5.3.2. Injections
5.3.3. Other ( Suspension)
6. Regional Analysis
6.1. North America
6.1.1. United States
6.1.2. Canada
6.2. Europe
6.2.1. UK
6.2.2. Germany
6.2.3. Italy
6.2.4. Spain
6.2.5. France
6.2.6. Rest of Europe
6.3. Asia-Pacific
6.3.1. China
6.3.2. India
6.3.3. Japan
6.3.4. Rest of Asia-Pacific
6.4. Rest of the World
7. Company Profiles
7.1. Alkem Laboratories Ltd.
7.2. AstraZeneca plc
7.3. Aurobindo Pharma Ltd.
7.4. Cadila Healthcare Ltd.
7.5. Chongqing LUMMY Pharmaceutical Co., Ltd.
7.6. Dr. Reddy’s Laboratories Ltd.
7.7. Glenmark Pharmaceuticals Inc.
7.8. Grünenthal GmbH
7.9. Laboratorios Saval S.A.
7.10. Lannett Co., Inc.
7.11. Mylan N.V
7.12. Novartis AG (Sandoz)
7.13. Sanofi SA
7.14. Stada Arzneimittel AG
7.15. Sun Pharmaceutical Industries Ltd.
7.16. Teva Pharmaceutical Industries Ltd.
1. GLOBAL ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
2. GLOBAL EROSIVE ESOPHAGITIS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
4. GLOBAL HELICOBACTER PYLORI INFECTION MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
5. GLOBAL OTHER DISEASE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
6. GLOBAL ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
7. GLOBAL BRANDED ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
8. GLOBAL GENERIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
9. GLOBAL ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
10. GLOBAL CAPSULES & TABLETS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
11. GLOBAL INJECTIONS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
12. GLOBAL OTHER DOSAGE TYPE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
13. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
14. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
15. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
16. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
17. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
18. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
19. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
20. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
21. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
22. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
23. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
24. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
25. REST OF THE WORLD ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
26. REST OF THE WORLD ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
27. REST OF THE WORLD ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
1. GLOBAL ESOMEPRAZOLE MARKET SHARE BY DISEASE, 2019 VS 2026 (%)
2. GLOBAL ESOMEPRAZOLE MARKET SHARE BY TYPE, 2019 VS 2026 (%)
3. GLOBAL ESOMEPRAZOLE MARKET SHARE BY DOSAGE TYPE, 2019 VS 2026 (%)
4. GLOBAL ESOMEPRAZOLE MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
5. US ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
6. CANADA ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
7. UK ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
8. FRANCE ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
9. GERMANY ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
10. ITALY ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
11. SPAIN ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
12. REST OF EUROPE ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
13. INDIA ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
14. CHINA ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
15. JAPAN ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
16. REST OF ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
